Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Tasly Biopharmaceuticals Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06724263CT.gov A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cervical Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| b1962 (this asset) | Tasly Biopharmaceuticals Co., Ltd. | P2 | CCC · 53 |
| Vinorelbine Ditartrate | UNICANCER | P2 | BBB |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | B |
| Carboplatin | Merck Sharp & Dohme LLC | P3 | B |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P3 | B |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Uganda Cancer Institute | P3 | B |
| Indocyanine Green | Istanbul University | P4 | B |
+42 more in the Cervical Cancer cohort
Other indications for b1962
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P2 | CCC · 53 |
| Ovarian Carcinoma | — | P2 | CCC · 53 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. b1962 in Cervical Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/b1962-cervical-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →